Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir. (LETERCOR)
Infections, Cytomegalovirus
About this trial
This is an interventional treatment trial for Infections, Cytomegalovirus focused on measuring Lung transplant, CMV prophylaxis, Cytomegalovirus
Eligibility Criteria
Inclusion Criteria (prospective cohort): Adults over 18 years old Lung transplant recipients (D+/R-) pre-transplant. Having an undetectable CMV polymerase chain reaction assay (PCR) within the 96 hours prior to the start of letermovir prophylaxis. Patients who have provided written informed consent. Exclusion Criteria (prospective cohort): HIV-infected patients. Patients with multivisceral transplant. Patients unable to comply with the follow-up protocol. Receiving a different antiviral prophylaxis other than ganciclovir prior to letermovir prophylaxis. Patients with concurrent renal and hepatic insufficiency. Inclusion Criteria (retrospective cohort): Adults over 18 years old. Lung transplant recipients (D+/R-) pre-transplant. Patients treated with Valganciclovir prophylaxis for 12 months. Patients transplanted within 2 years prior to the start of the study. Patients with a complete 13-month follow-up and comparable data to the prospective cohort to evaluate the study's primary variables. Exclusion Criteria (retrospective cohort): HIV-infected patients. Patients with multivisceral transplant.
Sites / Locations
- Hospital Universitario Reina Sofia
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Letermovir (prospective cohort)
Valganciclovir (retrospective cohort)
2 tablets of 240 milligrams (mg) Letermovir orally once daily. during 12 months
Retrospective cohort, of patients treated with Valganciclovir during 12 months